Novel Phenylimidazole Derivatives as PDE10A Enzyme Inhibitors

摘要

This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

主权项

1. A method of treating a subject suffering from a psychiatric disorder comprising administering a therapeutically effective amount of a compound having the structure of formula I wherein HET is a heteroaromatic group of formula II optionally substituted on the carbon atoms of the pyrazine ring of the HET group with up to three substituents R7-R9 individually selected from the group consisting of hydrogen, C1-C6 alkyl; halogen; cyano, halo(C1-C6)alkyl; aryl, alkoxy and C1-C6 hydroxyalkyl, and wherein * denotes the attachment point, -L- is selected from the group consisting of —CH2—CH2—, —S—CH2—, —CH2—S— and —CH═CH—, R1 is selected from the group consisting of H, C1-C6 alkyl; C1-C6 alkyl(C3-C8)cycloalkyl; C1-C6 hydroxyalkyl, CH2CN, CH2C(O)NH2, C1-C6 arylalkyl, and C1-C6 alkyl-heterocycloalkyl, and R2-R6 are selected individually from the group consisting of H, C1-C6 alkoxy and halogen, or a pharmaceutically acceptable acid addition salt thereof to a subject in need thereof wherein the psychiatric disorder is selected from the group consisting of schizophrenia, schizophreniform disorder and schizoaffective disorder.